|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
2553710 |
| 003 |
ICU |
| 005 |
20030522183900.0 |
| 008 |
970102s1997 nyu 001 0 eng c |
| 010 |
|
|
|a 96018671
|
| 020 |
|
|
|a 0824797485 (hardcover : alk. paper)
|
| 035 |
|
|
|a (ICU)BID22708552
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d OrLoB-B
|d OCoLC
|
| 041 |
0 |
|
|a eng
|
| 050 |
0 |
0 |
|a RC600
|b .N68 1997
|
| 060 |
|
0 |
|a WE 346 N937 1997
|
| 082 |
0 |
0 |
|a 616.97/8061
|2 20
|
| 245 |
0 |
0 |
|a Novel therapeutic agents for the treatment of autoimmune diseases /
|c edited by Vibeke Strand, David L. Scott,Lee S. Simon.
|
| 260 |
|
|
|a New York :
|b Dekker,
|c c1997.
|
| 263 |
|
|
|a 9609
|
| 300 |
|
|
|a xiv, 308 p.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
0 |
|g 1.
|t The Evaluation of Biological Agents /
|r Vibeke Strand and David L. Scott --
|g 2.
|t Anti-CD5/Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis /
|r John J. Cush --
|g 3.
|t Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis, Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis /
|r Thasia G. Woodworth and Karen Parker --
|g 4.
|t Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis /
|r Larry W. Moreland and William J. Koopman --
|g 5.
|t CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis /
|r F. C. Breedveld --
|g 6.
|t The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis /
|r David E. Yocum, Alan M. Solinger and John A. Lipani --
|g 7.
|t CAMPATH-1H Therapy in Autoimmune Diseases /
|r Richard A. Watts and John D. Isaacs --
|g 8.
|t CAMPATH-1H in Rheumatoid Arthritis: United States Experience /
|r David E. Yocum and Jeffrey M. Johnston --
|g 9.
|t Interferon-Gamma in the Treatment of Rheumatoid Arthritis /
|r Eric M. Veys, Herman Mielants and Gust Verbruggen --
|g 10.
|t Tumor Necrosis Factor Blockade in Rheumatoid Arthritis /
|r Michael J. Elliott, Marc Feldmann and Ravinder N. Maini --
|g 11.
|t Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNF[alpha]) Antibody, CDP571, in Rheumatoid Arthritis /
|r Ernest H. S. Choy and Gabriel S. Panayi --
|g 12.
|t Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis /
|r Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis and Alan Landay --
|g 13.
|t Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor /
|r Gary R. Margolies, William J. Koopman and Larry W. Moreland --
|g 14.
|t Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1 /
|r Arthur F. Kavanaugh and Peter E. Lipsky --
|g 15.
|t T-Cell-Receptor Peptide Therapy for Multiple Sclerosis /
|r Arthur A. Vandenbark, Dennis N. Bourdette, Ruth H. Whitham and Halina Offner --
|g 16.
|t T-Cell-Receptor Peptide Vaccination Studies in Rheumatoid Arthritis /
|r Louis W. Heck, Larry W. Moreland and William J. Koopman --
|g 17.
|t Oral Tolerance for the Treatment of Autoimmune Disease /
|r David A. Hafler and Howard L. Weiner --
|g 18.
|t Oral Tolerance /
|r David E. Trentham --
|g 19.
|t Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases /
|r Vibeke Strand and Martin L. Lee --
|g 20.
|t Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis /
|r Robert I. Fox and Randall E. Morris --
|g 21.
|t Leflunomide: A New Immunosuppressive Drug /
|r David L. Scott and Vibeke Strand --
|g 22.
|t An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases /
|r Vibeke Strand and Lee S. Simon.
|
| 650 |
|
0 |
|a Autoimmune diseases
|x Chemotherapy.
|
| 650 |
|
0 |
|a Autoimmune diseases
|x Immunotherapy.
|
| 650 |
1 |
2 |
|a Arthritis, Rheumatoid
|x therapy.
|
| 650 |
2 |
2 |
|a Autoimmune Diseases
|x therapy.
|
| 650 |
2 |
2 |
|a Antibodies, Monoclonal
|x therapeutic use.
|
| 650 |
2 |
2 |
|a Cytokines
|x antagonists & inhibitors.
|
| 650 |
2 |
2 |
|a Receptors, Antigen, T-Cell
|x immunology.
|
| 650 |
|
7 |
|a Autoimmune diseases
|x Chemotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00822665
|
| 650 |
|
7 |
|a Autoimmune diseases
|x Immunotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00822669
|
| 700 |
1 |
|
|a Strand, Vibeke.
|0 http://id.loc.gov/authorities/names/n88097237
|1 http://viaf.org/viaf/242886115
|
| 700 |
1 |
|
|a Scott, David L.,
|d 1951-
|0 http://id.loc.gov/authorities/names/n96802123
|1 http://viaf.org/viaf/315221756
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 035 |
|
|
|a (OCoLC)35121681
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 72abd4d6-348a-5bc8-bf40-74e7b85592ca
|s 7e74c3d8-8e0f-515c-82e1-42b8790abd81
|
| 928 |
|
|
|t Library of Congress classification
|a RC600.N680 1997
|l ASR
|c ASR-SciASR
|i 6052385
|
| 927 |
|
|
|t Library of Congress classification
|a RC600.N680 1997
|l ASR
|c ASR-SciASR
|e CRERAR
|b 44433309
|i 4734104
|
